You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
遠大醫藥(00512.HK)獲得治療嚴重過敏反應的腎上腺素自動注射筆商業化權利
格隆匯 08-02 18:09

格隆匯8月2日丨遠大醫藥(00512.HK)發佈公吿,集團近日與丹麥的ALK-AbellóA/S(“ALK公司”)達成產品獨家授權協議。集團將合計以1200萬歐元的首付款及里程碑費用,獲得ALK公司開發的治療嚴重過敏反應的Jext®預充式腎上腺素自動注射筆在中國大陸、中國澳門和中國台灣(“授權地區”)的長期獨家商業化權利。

ALK公司於1923年在丹麥成立,是一家專注於過敏免疫療法研發和製造的國際化公司,業務涉及全球41個市場,在丹麥,法國,西班牙和美國均設有生產基地。ALK公司產品Jext®預充式腎上腺素自動注射筆是一個內含腎上腺素無菌溶液的一次性自動注射器,通過將單劑量腎上腺素緊急注射到大腿肌肉外側(肌肉注射),可緊急治療因昆蟲叮咬、食物、藥物或運動而引起的突然且危及生命的嚴重過敏反應。目前,該產品已在歐洲、韓國以及中國香港地區上市。

集團作為中國最大的心腦血管急救藥研發、生產及銷售綜合企業之一,具有良好的品牌知名度。集團一直致力於急救領域新產品的開發及引進,本次與 ALK 公司的合作,為集團在急救藥物板塊引進了一款治療嚴重過敏反應的產品的同時,進一步豐富了急救板塊高壁壘藥品的產品線,為集團的中長期發展提供戰略儲備。

集團一直高度重視創新產品和先進技術的研發,以患者需求為核心,以科技創新為驅動,針對尚未滿足的臨牀需求,加大對全球創新產品和先進技術的投入,豐富和完善產品管線及產業佈局,採用“球化運營佈局,雙循環經營發展策略,形成國內國際雙循環聯動發展並相互促進的新格局,充分發揮集團的產業優勢和研發實力,快速將科技創新產品落地上市,為全球患者提供更先進更多樣的治療方案。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account